Between 1995 and 2002, nine cases of nontuberculous mycobacterium (NTM) were isolated from 462 allogeneic stem cell transplant (SCT) recipients (1.9%), and none from 139 autologous cases. They included three cases each of Mycobacterium fortuitum and M. chelonae, and single cases of M. scrofalaceum, M. gordonnae and M. avium complex. Seven cases were respiratory, including five cases requiring treatment, and two involved infected catheters and vascular conduits. Compared with nine cases of mycobacterium tuberculosis (MTB) isolated in the same period, NTM isolation occurred later after HSCT and involved more unrelated donors. Important risk factors for NTM infection included significant aGVHD (P ¼ 0.043), leukemia relapse (P ¼ 0.022), MUD and mismatch SCT (Po0.001) and existence of BO (Po0.001). Coinfection with aspergillus was common. Invasive NTM disease required prolonged antimicrobial treatment in five cases due to M. fortuitum and M. chelonae. With better MTB prophylaxis, intensive immunosuppression and better awareness, NTM has become an emerging threat in oriental allogeneic HSCT recipients. The cutoff between colonization and infection, and the threshold for starting treatment is unclear. NTM isolation is a marker for severe immunosuppression and poor prognosis. When there is doubt over species identity or extent of infection, broad-spectrum cover may be prudent.
stem cell transplantation
Hematopoietic stem cell transplant (HSCT) recipients are at risk of opportunistic infections, including mycobacterial infections. The specific spectrum of infections has varied with type of HSCT and local prevalence of mycobacterial species. In Caucasians, pathogenic Mycobacterium tuberculosis (MTB) is uncommon and most isolates are opportunistic non-tuberculous mycobacteria (NTM). Elaborate but empirical clinical, radiological and microbiological criteria have been developed in an attempt to distinguish between infection and colonization by NTM. 1 In Oriental countries such as Hong Kong, both MTB and NTM infections are commonly found in chronic lung disease and immunosuppressed patients. 2 The clinical feature of MTB infection in HSCT recipients in Oriental and Western patients has been extensively reviewed. [3] [4] [5] [6] [7] However, few series of NTM after HSCT have been published. [8] [9] [10] [11] [12] Furthermore, data from regions of high MTB prevalence have not been reported.
Material and methods

Patients
Clinical and microbiological records of consecutive cases of adult HSCT were reviewed. Standard conditioning regimens were used as reported, [13] [14] [15] [16] and cyclosporine (2 mg/ kg) and methotrexate were the standard graft-versus-host disease (GVHD) prophylaxis. GVHD incidence and survival have been previously reported, [13] [14] [15] [16] and were comparable with reported Caucasian series. Pre-HSCT screening included chest X-ray (CXR), history and surveillance sputum culture in all cases. Patients with a radiological or clinical history of MTB infection were given isoniazid prophylaxis (300 mg) for 6 months. 17 All patients received oral ciprofloxacin (500 mg Â 2/day), fluconzatole (200 mg/day) and acyclovir (200 mg Â 3/day) prophylaxis from conditioning until engraftment. In addition, mismatched or unrelated HSCT recipients (MUD) were given total gut decontamination (nystatin 1 : 10 000 5 ml Â 4/day, tobramycin 125 mg Â 2/day and vancomycin 250 mg Â 4/ day until engraftment), and ganciclovir (250 mg/day 3 Â / week until day 120), as reported. 18 Broadspectrum antibiotics and amphotericin B were administered for neutropenic fever. Twice weekly surveillance sputum, blood and urine microscopy and culture, cytomegalovirus surveillance and CXR were performed for all in-patients. The tests were repeated for fever or respiratory symptoms in outpatients.
Microbiological tests
Mycobacterial cultures and species identification were performed according to standard procedures. 19 Briefly, sterile specimens (eg body fluids) were inoculated directly into an egg-based medium, Lowenstein-Jensen medium, while nonsterile specimens (eg sputum) were decontaminated first. Cultures were kept at 30 and 351C for 6 weeks, and visible colonies were identified by conventional biochemical tests. Isolates of MTB were confirmed by manual one-tube nested polymerase chain reaction (PCR) for the IS6110 gene sequence. 20 Ambiguous isolates were referred to reference laboratories. Antimicrobial susceptibility was tested by agar proportion technique using Middlebrook 7H10 agar for M. tuberculosis. Susceptibility testing of NTB included agar disk diffusion and the E test according to specific isolates.
Statistical analysis
Published and possible risk factors associated with increased risk of mycobacterial infection after SCT were analyzed separately for MTB and SCT cases. These included allogeneic vs autologous SCT, unrelated/mismatch SCT vs matched sibling SCT, use of total body irradiation (TBI) in conditioning, severe (Gluckberg grade III or IV) acute GVHD, significant chronic GVHD, relapse of malignancy after SCT and bronchiolitis obliterans (o75% pre-SCT FEV 1 ). Kaplan-Meier analysis with Log-rank modeling was performed and cases were censored on the day of MTB/NTM infection, death or last followup. Cox model logistic regression was performed for multivariate analysis for the same factors. Calculations were performed using SPSS 10.0 software (SPSS, Chicago, IL, USA).
Results
Patients
The cohort included 601 cases of HSCT with 111 cases transplanted before 1995 and 490 cases transplanted from 1995 to 2002. They consisted of 462 allogeneic HSCT (261 men, 201 women, median age 35 (15-65) years, 74 unrelated/mismatched cases) and 139 autologous HSCT recipients (72 men, 67 women, median age 46 (14-67) years). The median follow-up time was 40 (1-146) months. Isoniazid prophylaxis was administered to 14 cases in whom mycobacteria was not found. Mycobaterium was isolated in 18 cases, including nine cases of pulmonary MTB (data not shown) and nine cases of NTM (Table 1) . These included three cases each of M. fortuitum and M. chelonae, and single cases of M. scrofalaceum, M. gordonnae and M. avium complex (MAC). Two patients suffered from an infected catheter or vascular graft. Of seven other NTM isolates, two were classified as colonization and were not treated specifically (see below). Only one patient fulfilled the American Thoracic Society (ATS) bacteriologic criteria of definite pulmonary disease with repeated isolates, while four were labeled as probable infections. 21 Notably, concomitant fungal infection was present in all five cases. One case each died before and during treatment, while NTM eradication was unsuccessful despite 18 months of treatment in one late death. The crude incidence of NTM and MTB isolation after allogeneic HSCT were 1.9% (n ¼ 9) and 1.5% (n ¼ 7), while the crude incidences after MUD SCT were 5.4% (n ¼ 4) and 1.4% (n ¼ 2), respectively. NTM was not isolated from 139 autologous HSCT cases. The median latency of NTM isolation after HSCT was longer than MTB (16.9 months vs 8.1 months). Smear positivity was reported in five cases (two MTB, three NTM) and the median times taken for culture identification were 23 (3-86) days for NTM and 53 (14-79) days for MTB. Nine patients (five NTM and four MTB) died of the underlying malignancy or sepsis.
Case reports
Suspected colonization. UPN 258 underwent matched sibling SCT for c-ALL in CR1 8 months after successful induction with the linker protocol. Pre-SCT CXR and sputum screening were normal. However, pre-SCT sputum screening was smear positive for AFB. The patient was asymptomatic and microscopic morphology suggested NTM, confirmed by positive culture of M. avium intracellulare. He underwent Cy-TBI conditioning in the absence of specific antituberculous therapy and engrafted on day 22 without pulmonary complications. There was no GVHD, but he suffered from leukemia relapse 5 years later and was successfully treated twice with chemotherapy and stem cell infusion. He died of second relapse at 68 months, without any subsequent radiological or microbiological evidence of NTM.
UPN 323 underwent sibling SCT for myeloma and achieved complete remission with BO and bilateral bronchiectasis, requiring cyclosporin, azathioprine and regular antibiotic treatment. At 68 months follow-up, M. scrofulaceum was isolated from sputum culture 80 days after resolution of a respiratory exacerbation. His clinical course and lung function remained stable 12 months later with no further NTM isolation.
Catheter-related infections. UPN 293 had Takayasu arteritis with an aortofemoral Teflon inverted Y vascular graft performed 6 years before SCT for CML. Mild chronic GVHD developed after successful donor lymphocyte infusion for molecular relapse at 14 months and was treated conservatively. She suffered from prolonged fever and malaise at 54-month follow-up. Extensive mid-graft thrombosis and inflammation was shown on angiogram and computerized tomography. An open debridement showed M. chelonae infection, and she underwent graft removal and 3 months treatment with amikacin, linezolid, azithromycin, with clarithromcyin maintenance.
UPN 823 suffered from fever after Hickman flushing and exit site inflammation 3 months after HSCT. Blood and swab cultures grew M. gordonae and symptoms subsided with catheter removal, without antibiotic treatment.
Pulmonary infection without leukemia. UPN 152 underwent MUD SCT for AML in CR2 and suffered from severe aGVHD followed by cGVHD affecting the skin and lungs. Despite CsA, azathioprine and inhaled steroids, her FEV1 decreased to 60% at 12-month follow-up. A bronchioalveolar lavage (BAL) performed for fever and left lower lobe infiltrate grew M. Fortuitum. She was treated with multiple antituberculous agents but remained sputum culture and smear positive. She also received prolonged treatment for pulmonary aspergillosis and nocardia, and died of respiratory failure 18 months later. UPN 703 received an overseas MUD SCT for AML in CR2, with mild aGVHD. He suffered from sudden rapid onset of BO at 11 months, unresponsive to azathioprine and inhalational steroids. At 16 months he suffered from fever, hypoxia and bilateral lung infiltrates requiring intubation and ventilatory support. A BAL showed M. chelonae and Aspergillus, and he was treated aggressively with ambisome, caspofungin and broadspectrum antibiotics with NTM coverage. He recovered after 1 month and was maintained on oral NTM drugs and itraconazole for 3 months, without fever or respiratory deterioration.
Pulmonary infection with leukemia. UPN 604 relapsed 10 months after MUD BMT for ALL, without GVHD. He achieved CR2 with chemotherapy with stem cell support from the same donor, but suffered from grade IV aGVHD with erythroderma, diarrhea and CMV reactivation. This was treated with ATG, gancyclovir, prophylatic ambisome and steroids, but he developed rapid onset of pulmonary infiltrates and died of septicemia. Sputum samples grew Aspergillus fumigatus and M. fortuitum post mortem.
Similarly, UPN 593 suffered from AML relapse 5 months after MUD SCT. She achieved CR after intensive chemotherapy and stem cells from same donor but suffered from grade IV aGVHD and rapid onset of BO, controlled with steroids, CsA and mycophenolate mofeteil. After 1 year, she was admitted with acute respiratory failure and bilateral lung infiltrates, requiring mechanical ventilation. A BAL showed smear-positive Aspergillus and AFB, but she died despite empirical ambisome and anti-TB treatment. M. chelonae was identified post mortem.
The unique leukemia course of UPN 375 has been reported. 22 She underwent SCT for CML with moderate cGVHD. At 3-year FU, she suffered from fever and skin infiltrations. A skin biopsy showed granuloma annulare. Empirical mycobacterial treatment was commenced. This was followed by cytopenia, with circulating blasts and pulmonary infiltrates. Subsequent investigations confirmed AML of donor origin, while sputum and urine specimen grew M. fortuitum and A. fumigatus. She achieved CR for 6 months with three courses of intensive chemotherapy, supported with antimycobacterium drugs and ambisome. Although there was no recurrence of severe infection, she died of refractory donor AML relapse.
Risk factors for mycobacterial infection. The distribution of clinical risk factors among background, NTM and MTB cases are shown in Table 2 . The significant risk factors for NTM infection included significant aGVHD (P ¼ 0.043), leukemia relapse (P ¼ 0.022), MUD and mismatch SCT (Po0.001) and existence of BO (Po0.001). On multivariate analysis, only unrelated or mismatch SCT and BO remained significant. On the other hand, risk factors for MTB appeared to be slightly different in our latest cohort. On univariate analysis, pronounced cGVHD (P ¼ 0.049) and BO (P ¼ 0.032) were significant factors. Interestingly, the use of TBI conditioning (mainly for ALL cases) was associated with reduced risk of MTB (P ¼ 0.037). On multivariate analysis, however, the effect of TBI disappeared, while mismatch and unrelated SCT become a significant risk factor.
Discussion
The incidence of pulmonary MTB and NTM isolation in the Hong Kong general population has remained stable for the past three decades at 112.3 and 10.7 per 100 000/year, respectively. 23 Among NTM isolates, only 16.7 and 2.3% represented progressive disease and persistent carriage. 24 Among 1798 registered HIV carriers, the incidences of MTB and NTM from 1985 to 2001 were 126 (7%) and 19 (1%) cases, respectively. 25 Unlike with HIV carriers and normal hosts, the incidence of NTM isolation in HSCT recipients was comparable to that of MTB. This may be related to improved MTB prophylaxis and distinct predisposing factors for NTM growth, including prolonged recurrent neutropenia and chronic lung damage due to GVHD. Our group previously reported a crude incidence of 5.5% of MTB among 183 HSCT cases from 1991 to 1994, with a median onset of 5 months and increased risks with allogeneic HSCT, GVHD and pulmonary irradiation. 17 Retrospectively, the association with TBI may be related to the routine use of Bu-Cy-TBI for unrelated/ mismatch conditioning, which was abandoned after 1997. This update showed an apparently reduced crude incidence of MTB, and confirmed the importance of GVHD. It also showed that even with vigorous pre-HSCT screening and prophylaxis, late-onset MTB infection may still complicate chronic BO and may be more common among unrelated/ mismatch SCT recipients.
There are few studies on the relative significance of NTM among mycobacterial infections in HSCT patients. The problem was first reported in four cases published 20 years ago. 11, 26 In two subsequent series from Minneapolis and Seattle, 59 cases of NTM were reported among 8500 HSCT recipients over 20 years (incidence 0.4-1.11%). The incidence was 5-10 times higher than that of MTB infection (Table 3) . Approximately equal numbers of catheter-related infections (usually due to M. fortunitum/chelonae) and pulmonary isolates (M. avium intracellulare, M. fortuitum/ chelonae) were reported. Four Oriental series involving 1200 patients did not report any NTM cases among 14 positive isolates, [4] [5] [6] [7] although recent case reports have appeared from the region. 9 This could be due to increased recognition and improved mycobacterial identification. 27 Our present cohort showed both similarities and differences compared with those of Caucasian NTM reports, and illustrated some practical points in clinical management. In our area of high MTB prevalence, isolation of NTM and MTB occurs at roughly equal frequencies. Furthermore, as illustrated, the clinical factors predisposing to NTM and MTB infections showed much similarity and overlap. Hence, the finding of a positive acidfast bacillus smear or mycobacterium culture in an Oriental HSCT recipient presents a treatment dilemma, since MTB is still highly probable. The use of the tuberculin skin test is limited by universal BCG vaccination, while the use of PCR to confirm MTB is not always reliable. 28 For critically ill cases, empirical treatment for MTB is warranted, and can be modified or stopped after NTM species isolation. 29 In the absence of fever and respiratory symptoms, however, observation and repeated sampling may also be appropriate.
Clinical infections by NTM fall into two main categories: early-onset catheter-related infection and late-onset infection associated with chronic lung disease. Our incidence of catheter infection appeared to be lower compared with Caucasian studies, possibly related to our practice of early removal of central venous catheters, and the availability of a comprehensive community nurse home-care of catheter hygiene in Hong Kong. The removal of infected foreign material is essential and for deep implants, extensive surgery, and prolonged antibiotic treatment may be needed. For pulmonary isolates, colonization and infection may be indistinguishable in the bronchiectatic and scar tissues in BO patients. The Seattle and Minnesota series reported 30% and 52% of isolates as colonization, mainly involving M. avium. The issue was further complicated by the commencement of NTM treatment in 25% and septic death in 50% of 'colonization' cases in the former series. It must be recognized that clinical definitions of infection and colonization for immunocompromised and immunocompetent hosts 21 are empirical, and mainly apply to the M. avium, M. abscessus and M. kansasii species. In Chinese patients, M. fortuitum/chelonae appeared to be more prevalent. Similar to Western experience, this is rarely a benign finding. Our statistical analysis suggested that the presence of BO and mismatched/unrelated SCT are independent risks factors for NTM infection, while disease relapse and aGVHD might also be implicated. Hence, NTM infections after autologous HSCT are rarely involved. 30 Furthermore aspergillus and other pathogens are concurrently present in up to 80% of cases. 10 Hence, in the appropriate clinical setting, single isolates (especially for more virulent NTM species) warrant prompt treatment. Eradication of NTM may be impossible and mycobacteria may contribute to continued pulmonary destruction. Even with adequate treatment, the death rates in these respiratory cripples remained high. 10 It remains to be seen if our NTM experience is reproduced by other Oriental centers, and whether more vigorous treatment will change the natural history of the disease.
